edotreotide has been researched along with Emesis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bartolomei, M; Bodei, L; Caracciolo, M; Chinol, M; Cremonesi, M; Grana, C; Mäcke, HR; Paganelli, G; Rocca, P; Zoboli, S | 1 |
| Barone, R; Bouterfa, H; Carlier, P; Chen, T; de Camps, J; Jamar, F; Krenning, EP; Kvols, LK; Labar, D; Mathieu, I; Pauwels, S; Schran, H; Smith, MC; Valkema, R; Walrand, S | 1 |
2 trial(s) available for edotreotide and Emesis
| Article | Year |
|---|---|
Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study.
Topics: Adult; Aged; Amino Acids; Biomarkers, Tumor; Blood Platelets; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Hemoglobins; Humans; Kidney; Lymphocytes; Male; Maximum Tolerated Dose; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Octreotide; Radiation-Protective Agents; Radiometry; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Renal Insufficiency; Vomiting; Yttrium Radioisotopes | 2003 |
86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion.
Topics: Adult; Aged; Amino Acids; Arginine; Cohort Studies; Cross-Over Studies; Dizziness; Drug Combinations; Female; Humans; Infusions, Intravenous; Kidney; Lysine; Male; Metabolic Clearance Rate; Middle Aged; Neuroendocrine Tumors; Octreotide; Organ Specificity; Radiation Dosage; Radiation Injuries; Radiation-Protective Agents; Radiometry; Radiopharmaceuticals; Tissue Distribution; Tomography, Emission-Computed; Vomiting; Yttrium Radioisotopes | 2003 |